Author: GDIT, (800) 688-6696
Clinical Policy, Routine Costs in Clinical Trial Services for Life Threatening Conditions, 1A-39 has been revised. The revisions, which will become effective July 1, 2019, provide clearer explanations and definitions regarding coverage for routine costs in clinical trial services for life-threatening conditions. Descriptions will be added for the following:
- Clinical trial phases 0-IV
- Investigational Device Exemption (IDE)
- Humanitarian Use Device (HUD)
- Humanitarian Device Exemption (HDE)
- Investigational New Drug (IND)
Definitions will be revised or added for the following:
- Qualifying clinical trial
- Routine costs
- Life-threatening condition
- Informed consent
- ClinicalTrials.gov Identifier (NCT number)
- Institutional Review Boards (IRB)
Prior approval requirements will be clarified for clinical trials in which the underlying service, product or procedure requires prior approval.